Status:
WITHDRAWN
Efficacy and Safety Study in Patients Suffering From Knee Osteoarthritis
Lead Sponsor:
Pierre Fabre Medicament
Conditions:
Knee Osteoarthritis
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
The primary objective of this study is to compare a combination of hyaluronic acid and chondroitin sulfate (V0220) to Hyalgan® on pain relief in patients with symptomatic knee osteoarthritis (OA) over...
Eligibility Criteria
Inclusion
- presenting with uni or bilateral medial and/or lateral femorotibial osteoarthritis of the knee evolving for more than 6 months
- patients taking analgesic medications for at least 3 months prior to randomisation and dissatisfied with their current therapy
Exclusion
- isolated symptomatic femoropatellar osteoarthritis
- target knee prothesis
- having undergone an articular lavage, or an arthroscopy or any surgery on the target knee in the 6 months preceding randomisation,
- target knee osteoarthritis with clinical joint effusion at selection and at randomization
- body mass index (BMI) greater than or equal to 30,
- patient having received any corticosteroid treatment by any administration route (other than inhalers, ocular, auricular route) in the month preceding randomisation,
- patient having received intra-articular steroid injection in the target knee within the month preceding randomisation or patient having received intra-articular hyaluronic acid in the target knee in the 6 months preceding randomisation
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01469507
Last Update
February 21 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.